PURE Bioscience, Inc.
PURE · OTC
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Revenue | $2,202,000 | $1,963 | $1,877 | $1,853 |
| % Growth | 112,075.2% | 4.6% | 1.3% | – |
| Cost of Goods Sold | $899,000 | $811 | $906 | $853 |
| Gross Profit | $1,303,000 | $1,152 | $971 | $1,000 |
| % Margin | 59.2% | 58.7% | 51.7% | 54% |
| R&D Expenses | $316,000 | $302 | $297 | $319 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3,259,000 | $3,981 | $4,302 | $4,106 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $60 | -$4 | $0 |
| Operating Expenses | $3,575,000 | $4,343 | $4,599 | $4,425 |
| Operating Income | -$2,272 | -$3,131 | -$3,943 | -$3,425 |
| % Margin | -0.1% | -159.5% | -210.1% | -184.8% |
| Other Income/Exp. Net | -$127 | -$219 | -$18 | $233 |
| Pre-Tax Income | -$2,399 | -$3,350 | -$3,961 | -$3,491 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,399 | -$3,350 | -$3,961 | -$3,497 |
| % Margin | -0.1% | -170.7% | -211% | -188.7% |
| EPS | -0.021 | -0.03 | -0.036 | -0.039 |
| % Growth | 28.4% | 16% | 9.6% | – |
| EPS Diluted | -0.021 | -0.03 | -0.036 | -0.039 |
| Weighted Avg Shares Out | 111,863 | 111,856 | 111,404 | 88,835 |
| Weighted Avg Shares Out Dil | 111,863 | 111,856 | 111,404 | 88,835 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $299,000 | $155 | $14 | $6 |
| Depreciation & Amortization | $2 | $148 | $117 | $213 |
| EBITDA | -$2,098 | -$3,047 | -$3,830 | -$3,272 |
| % Margin | -0.1% | -155.2% | -204% | -176.6% |